Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
AffiliationDepartments of Endocrinology and Clinical Pharmacology, Christie Hospital and Holt Radium Institute, Manchester
MetadataShow full item record
AbstractPostmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily. After 3 days at this dose dexamethasone 1 mg daily was added and this combination was continued until disease progression occurred. Partial remission was seen in 26% and stabilization of previously progressive disease in a further 13% of the first twenty-three patients studied. During therapy with trilostane alone significant increases in DHEAS, androstenedione, 17-hydroxypregnenolone, progesterone, testosterone and oestradiol were seen. A significant fall in oestrone concentration occurred at the same time. After dexamethasone was added the elevated steroid concentrations fell back to the baseline while oestrone remained depressed below this and testosterone was also significantly lowered. No change was seen in cortisol or ACTH concentration while patients were on trilostane alone but cortisol levels were undetectable after dexamethasone was added though, in most patients, ACTH remained detectable. There was no change in the ratio of delta 5:delta 4 steroids at any stage of therapy but a highly significant increase in the androstenedione: oestrone ratio was seen. We conclude that in long-term use in vivo it is difficult to demonstrate that trilostane inhibits 3 beta-hydroxysteroid dehydrogenase but it may produce inhibition of aromatase.
CitationHormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. 1985, 23 (4):413-21 Clin Endocrinol
- Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment.
- Authors: Borkowski A, L'hermite M, Dor P, Longeval E, Rozencweig M, Muquardt C, Van Cauter E
- Issue date: 1977 May
- Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure.
- Authors: Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW
- Issue date: 1990 Apr
- Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
- Authors: Sieber-Ruckstuhl NS, Boretti FS, Wenger M, Maser-Gluth C, Reusch CE
- Issue date: 2006 Jul
- Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer.
- Authors: Williams CJ, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster DJ, Rowland C, Tyrrell C
- Issue date: 1987 Dec
- Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
- Authors: Alexieva-Figusch J, de Jong FH, Lamberts WJ, van Gilse HA, Klign JG
- Issue date: 1987 Sep